Charter Medical, a Lydall subsidiary, has received CE Mark approval for its next generation cell freeze cryogenic storage containers used for hematopoietic progenitor cells (HPC's).
The next generation storage containers are available from a size range of 50 mL to 750 mL and also have durability when frozen at ultralow (-196*C) temperatures.
Charter provides products to separate, contain and transport vital fluids in the blood and cell therapy, biotech and pharmaceutical industry markets.
Charter Medical Global Marketing and Sales vice president Joe Petrosky said these products serve several high growth markets including cellular therapy and have already received acceptance at several customers in the US.